Intractable and rare diseases research in Asia

スポンサーリンク

概要

• 論文の詳細を見る

• Intractable and rare diseases are an important public health issue and a challenge to medical care. In recent years, much progress has been made in the United States (US), the European Union (EU), and some parts of Asia including Japan, South Korea, and Taiwan, involving specific legislation to encourage discovery and development of orphan drugs, patients advocacy organizations to provide vast information on intractable and rare diseases and improve patients access to healthcare, special research programs to strengthen basic and applied research on intractable and rare diseases, and so on. While China is also actively promoting regulation of intractable and rare diseases, but still lags far behind the US, EU, Japan, and other countries and regions with orphan drug legislation. Based on systematic analysis of the current status and future perspectives for intractable and rare diseases in Asia, we recommend that three important aspects of support from government, patients advocacy organizations and rare disease registry networks, special research programs and global information exchange platform, should be given great attention in promoting the development of intractable and rare diseases research in Asian countries.

• 特定非営利活動法人 バイオ＆ソーシャル・サイエンス推進国際研究交流会の論文

特定非営利活動法人 バイオ＆ソーシャル・サイエンス推進国際研究交流会 | 論文

• Traditional Chinese medicine and related active compounds: A review of their role on hepatitis B virus infection
• The etiologies of new cases of cerebral venous sinus thrombosis reported in the past year
• The supercritical CO2 extract from the skin of Bufo bufo gargarizans Cantor blocks hepatitis B virus antigen secretion in HepG2.2.15 cells
• HDAC6: Physiological function and its selective inhibitors for cancer treatment
• High prevalence of HIV-associated neurocognitive disorder in HIV-infected patients with a baseline CD4 count ≤ 350 cells/μL in Shanghai, China

もっと見る

スポンサーリンク